Clinical Trials
16 trialsNCT02568267 2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT04302025 2026-05-22
NAUTIKA1
Genentech, Inc.
Phase 2 Recruiting
NCT05862285 2026-05-12
UmbrellaMAX
Hoffmann-La Roche
Phase 3 Recruiting
NCT04589845 2026-05-08
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT05170204 2026-05-06
HORIZON 1
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT02650401 2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT03178552 2026-03-09
B-FAST
Hoffmann-La Roche
Phase 2/3 Active not recruiting
NCT04603807 2026-02-27
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT03498521 2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2 Completed
NCT05834348 2025-03-30
DELINOR
Pfizer
Completed
NCT04632992 2025-01-08
MyTACTIC
Genentech, Inc.
Phase 2 Completed
NCT03056599 2021-09-24
Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma
Presage Biosciences
Phase 1 Completed
NCT02097810 2021-06-09
STARTRK-1
Hoffmann-La Roche
Phase 1 Completed
NCT03961100 2020-09-07
A Performance and Bioavailability Study of Entrectinib in Healthy Volunteers.
Genentech, Inc.
Phase 1 Completed
NCT03066661 2019-04-26
Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions
Hoffmann-La Roche
No longer available
NCT03330990 2018-08-21
Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients
Hoffmann-La Roche
Phase 1 Completed